![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright © 2005, European Molecular Biology Organization Receptor-stimulated oxidation of SHP-2 promotes T-cell adhesion through SLP-76–ADAP 1Department of Microbiology and Immunology, University of Maryland School of Medicine, Rockville, MD, USA 2Department of Pathology, University of Maryland School of Medicine, Rockville, MD, USA 3Laboratory of Biophysical Chemistry, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA 4Department of Immunology, George Washington University School of Medicine, Washington, DC, USA 5Veritas Inc., Rockville, MD, USA aDepartment of Microbiology and Immunology, University of Maryland School of Medicine, 15601 Crabbs Branch Way, Rockville, MD 20855, USA. Tel.: +1 301 738 0468; Fax: +1 301 517 0344; E-mail: willmark/at/usa.redcross.org Received January 26, 2005; Accepted May 11, 2005. This article has been cited by other articles in PMC.Abstract Receptor-stimulated generation of intracellular reactive oxygen species (ROS) modulates signal transduction, although the mechanism(s) is unclear. One potential basis is the reversible oxidation of the active site cysteine of protein tyrosine phosphatases (PTPs). Here, we show that activation of the antigen receptor of T cells (TCR), which induces production of ROS, induces transient inactivation of the SH2 domain-containing PTP, SHP-2, but not the homologous SHP-1. SHP-2 is recruited to the LAT–Gads–SLP-76 complex and directly regulates the phosphorylation of key signaling proteins Vav1 and ADAP. Furthermore, the association of ADAP with the adapter SLP-76 is regulated by SHP-2 in a redox-dependent manner. The data indicate that TCR-mediated ROS generation leads to SHP-2 oxidation, which promotes T-cell adhesion through effects on an SLP-76-dependent signaling pathway to integrin activation. Keywords: adhesion, reactive oxygen species, protein tyrosine phosphatase, signal transduction, T lymphocyte Introduction Regulation of cellular functions in response to exogenous stress, for example, oxidative stress, irradiation, etc., has been characterized in evolutionarily conserved systems from microbial organisms to plants and mammals. It is now clear that cell surface receptors also utilize changes in redox balance to regulate signal transduction. Receptor stimulation with ligands as diverse as PDGF (Meng et al, 2002), insulin (Mahadev et al, 2001) or angiotensin II (Ushio-Fukai et al, 1998) induces the intracellular production of reactive oxygen species (ROS). In these studies, ROS function as requisite second messengers, regulating protein kinase activation, gene expression and/or proliferative responses. The mechanism(s) for this redox-dependent regulation of biologic responses, however, remains unclear. One redox-sensitive target that regulates signaling is the family of protein tyrosine phosphatases (PTPs), which have an oxidation-sensitive, active site cysteine (Rhee et al, 2000). Insulin-induced ROS generation leads to oxidative inactivation of the PTPs, PTP1B and TC45 (Mahadev et al, 2001; Meng et al, 2004). Both phosphatases control phosphorylation of the insulin receptor or associated proteins, and insulin-induced PTP oxidation regulates downstream signaling. Oxidative inactivation of PTPs was also induced by ROS generation associated with stimulation with EGF (PTP1B) (Lee et al, 1998) or PDGF (LM-PTP, SHP-2, PTEN) (Chiarugi et al, 2001; Meng et al, 2002; Kwon et al, 2004) and this is a pivotal step in the biological effects of these ligands. Previous studies have shown that signal transduction through the antigen receptor of T cells (TCR) can also be regulated by receptor-mediated production of ROS (Jackson et al, 2004). In mature T cells, TCR crosslinking induces rapid (within 2–4 min) ROS generation and the data indicate that TCR-stimulated ROS production regulates activation of MAPK, cytokine secretion and gene expression (Devadas et al, 2002; Kwon et al, 2003). In particular, TCR-induced production of hydrogen peroxide selectively inhibits activation of the MEK/Erk pathway (Kwon et al, 2003). However, the mechanisms by which ROS regulate TCR signaling are still poorly understood. Exposure to exogenous oxidants leads to oxidative inactivation of PTPs in T cells (O'Shea et al, 1992), but there is no evidence to date on the effects of TCR-induced ROS production on PTP function. TCR signaling depends upon coordinated interactions of multiple signaling pathways, including PTPs, protein kinases and adapter proteins (e.g., LAT, SLP-76, Grb2, Gads) that ‘nucleate' key proteins (Jordan et al, 2003; Mustelin et al, 2003). The membrane-localized adapter LAT (linker for activation of T cells), upon tyrosine phosphorylation, recruits a number of proteins via their SH2 domains (e.g., Grb2, Gads, PLCγ1) (Wange, 2000). Gads (Grb2-like adapter downstream of Shc) is an adapter protein that, via one of its SH3 domains, interacts with the proline-rich domain of SLP-76 and recruits it to LAT and the membrane (Liu et al, 2001). In addition to the proline-rich domain, SLP-76 (SH2-containing leukocyte-specific protein of 76 kDa) has multiple functional interaction domains, including phosphorylated tyrosines and an SH2 domain (Myung et al, 2001) that bind proteins, including Vav1, Nck, Itk and ADAP (Myung et al, 2001). ADAP (adhesion- and degranulation-promoting adaptor protein), also known as Fyn SH2-binding protein (Fyb) or SLAP-130, binds the SH2 domain of SLP-76 upon ADAP phosphorylation (Peterson, 2003). ADAP is necessary for optimal T-cell responses and the inside-out activation of integrins (Griffiths et al, 2001; Peterson et al, 2001). Thus, the adapters Gads, SLP-76 and ADAP are critical regulators of T-cell development and TCR signaling pathways. The goal of the current report was to investigate the molecular basis for redox control of TCR signal transduction by intracellular production of ROS. In the current study, we show that SHP-2 is oxidized by ROS produced upon TCR stimulation and that the active site cysteine is the primary site of oxidation. We further identify a site of action for SHP-2 in dephosphorylation of Vav1 and ADAP associated with SLP-76, although it does not dephosphorylate SLP-76 itself. The data support the hypothesis that SHP-2 exerts a negative role in dephosphorylation of ADAP and Vav1, which limits TCR-induced adhesion and LFA-1 clustering. TCR-induced ROS production selectively inhibits SHP-2-mediated dephosphorylation of Vav1 and ADAP associated with SLP-76, leading to redox-dependent changes in TCR-stimulated adhesion and integrin clustering. Results TCR-induced oxidation of SHP-2 Our previous data have demonstrated that TCR-induced production of hydrogen peroxide selectively inhibited activation of the MEK/Erk kinase pathway (Kwon et al, 2003; Jackson et al, 2004). SHP-2 has been shown to promote ERK activation in T cells (Frearson and Alexander, 1998). Therefore, we analyzed TCR-induced oxidation of SHP-2. A biotinylated thiol reactive probe was used to label reduced/nonoxidized thiols in whole-cell lysates under anaerobic conditions. The labeling conditions lead to selective alkylation of reactive thiols, such as active site cysteines of PTPs (Kim et al, 2000). Loss of biotin incorporation into immunoprecipitated SHP-2 indicates oxidation of reactive thiols (Figure 1A
To test the selectivity of TCR-induced ROS generation in PTP oxidation, oxidation of SHP-1 was measured. SHP-1 also has tandem SH2 domains, exhibits similar substrate specificity as SHP-2 and has been proposed to affect TCR signal transduction (reviewed in Neel et al, 2003). Under conditions in which SHP-2 oxidation was observed, little or no oxidation of SHP-1 was detected (Figure 1C Although the labeling procedure is designed to detect oxidation of the active site cysteine, iodoacetamide could react with other free thiols in SHP-2. Therefore, Jurkat T cells were transfected to express (His)6-tagged SHP-2 in which the active site cysteine was mutated to serine (SHP-2(C/S)). Due to the presence of the (His)6 tag, the ectopically expressed SHP-2 has a slower mobility in gels and can be distinguished from endogenous SHP-2. In unstimulated cells, biotin labeling of endogenous SHP-2 was readily detected, but there was little incorporation of the label into the SHP-2(C/S) protein (Figure 1E The labeling procedure above measures a loss of reactivity in protein thiols under nondenaturing conditions. The results could be affected by accessibility of thiols, and interpretation of the data relies upon the ability to detect decreased biotin incorporation. Therefore, SHP-2 oxidation was assayed using a method in which reduced thiols were blocked under denaturing conditions and the reversibly oxidized thiols were re-reduced and labeled with iodoacetamide-biotin (Kwon et al, 2004). This ‘positive labeling' of oxidized thiols will show a gain of signal upon thiol oxidation induced by TCR-stimulated ROS generation. Consistent with the results in Figure 1
The two labeling approaches suggested that SHP-2 was more sensitive to intracellular ROS than SHP-1. This was directly tested by exposing Jurkat cells to graded concentrations of hydrogen peroxide and measuring oxidation of both SHP-1 and SHP-2 by the loss of biotin-iodoacetamide incorporation as in Figure 1 Antioxidants and antioxidant enzymes were used to indicate a causal role for TCR-induced ROS generation in SHP-2 oxidation. Coincubation of mouse T cells with the antioxidant N-acetyl-cysteine (NAC) inhibited the loss of SHP-2 labeling, suggesting that ROS produced upon TCR stimulation were responsible for the loss of labeling (Figure 2E Expression of inactive SHP-2 in T cells The active site mutant of SHP-2 (SHP-2(C/S)) was expressed in cells to mimic the conditions in which SHP-2 was oxidatively inactivated. Expression of such mutated PTPs has also been used to identify potential phosphatase substrates (Neel and Tonks, 1997). Overexpression of wild-type SHP-2 (SHP-2 WT) was used to control for the effects of increased SHP-2 protein and the possible effects of increased SHP-2 activity in cells. Anti-HA immunoprecipitation from anti-CD3-stimulated cells expressing HA-tagged SHP-2(C/S) showed increased association of multiple phosphoproteins (Figure 3A
Immunoprecipitation of LAT from Jurkat cells transfected to express SHP-2(C/S) and SHP-2 WT showed minor changes in associated phosphoproteins upon stimulation with anti-CD3 (Figure 3B Grb2 and Gads are the major adapter proteins that bind LAT. Grb2 immunoprecipitates showed minor differences in the association of tyrosine phosphorylated proteins in cells expressing either wild-type or mutant SHP-2 (Figure 3E and F Effect of SHP-2(C/S) on Gads- and SLP-76-associated proteins Analysis of phosphoproteins that co-immunoprecipitated with Gads from TCR-stimulated cells expressing SHP-2(C/S) extended the results observed in LAT precipitates. There was an increase (approximately two-fold by densitometry) in tyrosine phosphorylation of bands corresponding to ADAP and Vav1 as compared to cells expressing SHP-2 WT or vector (Figure 4A
The consistent effect on Vav1 phosphorylation led us to measure directly changes in Vav1 phosphorylation in Vav1 immunoprecipitates (Figure 4C Direct immunoprecipitation of ADAP supported the observation that SHP-2(C/S) expression led to increased ADAP phosphorylation (Figure 4D The SH2 domains of SHP-2 and SHP-1 show selective recognition, and are generally not interchangeable (Neel et al, 2003). Nevertheless, expression of high levels of SHP-2(C/S) might alter SHP-1 function. To test the potential role of SHP-1 in TCR-mediated changes in phosphorylation of proteins in the Gads–SLP-76 complex, SHP-1(C/S) was expressed side by side with SHP-2(C/S) in Jurkat cells (Supplementary Figure 3). In cells expressing SHP-1(C/S), anti-SLP-76 immunoprecipitates did not show the increase in phosphorylated Vav1 or phospho-ADAP that was observed in cells expressing SHP-2(C/S). In contrast, there was decreased phosphorylation of bands corresponding to ADAP, LAT and Vav1. Therefore, the data support a model in which SHP-2 associates with a Gads–SLP-76 complex but does not target SLP-76 itself as a substrate. The data suggest that SHP-2 controls phosphorylation of Vav1 bound to SLP-76 and regulates the phosphorylation of ADAP and therefore its association with SLP-76. Role of ROS in protein association with Gads–SLP-76 SHP-2(C/S) was expressed to mimic oxidatively inactivated SHP-2 in cells where ROS generation was occurring. Quenching TCR-induced ROS production with antioxidants, which inhibited SHP-2 oxidation (Figure 2
The effects of Prx II (Figure 5A Effects of ROS and SHP-2 on adhesion ADAP association with SLP-76 has been proposed to regulate TCR-induced adhesion of T cells through inside-out signaling to β-integrins (Griffiths et al, 2001; Peterson et al, 2001). Using adhesion to fibronectin-coated plates, SHP-2(C/S) expression significantly increased TCR-stimulated adhesion (Figure 6A
Inside-out signaling to integrins involves TCR-stimulated clustering of LFA-1 (Peterson, 2003). Fluorescent microscopic analysis of LFA-1 in T cells expressing SHP-2(C/S) or Prx II supported the adhesion data (Figure 6B
Discussion Appropriate signal transduction and optimal cell activation require a balance between the activity of protein tyrosine kinases and PTPs. Recent evidence has shown that receptor-mediated generation of ROS can act to fine-tune this balance (Finkel, 2003). Herein, we show that the PTP SHP-2, but not the highly homologous SHP-1, is transiently oxidized in T cells by TCR-stimulated generation of ROS. Furthermore, we have identified two putative SHP-2 substrates, ADAP and Vav1, in T cells. The data suggest that SHP-2 oxidation promotes TCR-induced phosphorylation of ADAP and Vav1 in the Gads–SLP-76 complex and these changes increase integrin clustering and T-cell adhesion. Signal transduction by ligands such as EGF, PDGF or insulin leads to generation of intracellular ROS and redox regulation of PTP function (Rhee et al, 2005). TCR-stimulated ROS production induced oxidation of SHP-2, primarily at the active site cysteine. SHP-2 oxidation was transient, returning to baseline within 15–30 min after stimulation. Oxidative inactivation of PTPs by ROS can be reversible or irreversible, depending upon the oxidation state (Claiborne et al, 1999). Enzymatic reduction of the active site thiol by glutaredoxin or thioredoxin can lead to recovery of phosphatase activity (Lee et al, 1998; Barrett et al, 1999). Using positive labeling, SHP-2 was found to have DTT-reducible form(s) of oxidized thiols upon TCR-induced ROS generation. Based upon previous reports of cysteine oxidation in PTPs, these may include sulfenic acids or disulfides formed with nearby intraprotein thiols or glutathione (Rhee et al, 2005). Recently, it has been shown that, upon oxidation of the active site thiol, PTP1B formed a novel intraprotein cyclic sulfenyl amide (Salmeen et al, 2003; van Montfort et al, 2003). These modifications are important because they are reversible and protect the active site thiol from further irreversible oxidation. It appears that oxidation of SHP-2 is somewhat selective in T cells. SHP-1, the only other known mammalian PTP with tandem SH2 domains (Neel et al, 2003), was not detectably oxidized upon TCR stimulation and required higher amounts of exogenous hydrogen peroxide to demonstrate similar levels of thiol oxidation as SHP-2. Interestingly, PDGF-stimulated ROS generation also induced oxidation of SHP-2, but not SHP-1 (Meng et al, 2002). This may be due to different spatial orientation of the active site cysteines in relationship to positively charged residues in the active site pocket of the two phosphatases (Groen et al, 2005). The results may also reflect selective oxidation of PTP(s) present in a specific subcellular fraction by localized production of ROS. Consistent with this model, PDGF-induced SHP-2 oxidation did not occur in cells expressing a mutated PDGF receptor that was unable to recruit SHP-2 (Meng et al, 2002). The current data suggest that SHP-2 associates with SLP-76 upon TCR stimulation and oxidized SHP-2 is localized within the Gads–SLP-76 complex. Association of inactive SHP-2 with proteins may be due to prolonged binding to phosphorylated substrates (Frearson and Alexander, 1998; Meng et al, 2002). In cells expressing the inactive SHP-2(C/S), both anti-Gads and anti-SLP-76 immunoprecipitates showed increased SHP-2 association. Similarly, immunoprecipitation of HA-SHP-2 (C/S) also revealed a limited association of SHP-2 with tyrosine phosphorylated proteins primarily involved in a LAT–Gads–SLP-76 complex. Coexpression of SHP-2(C/S) and Prx II suggested localized redox regulation of SHP-2, since combined expression partially reversed the effect of either one alone. Thus, expressing SHP-2(C/S) to inhibit/compete for the increased levels of active SHP-2 produced by expression of Prx II led to increased ADAP phosphorylation and SLP-76 association when compared to vector controls or cells expressing Prx II alone. Conversely, inhibiting localized oxidation of SHP-2 with Prx II expression increased the amount of active SHP-2 in the Gads–SLP-76 complex. This competed with inactive SHP-2(C/S), dephosphorylated ADAP and decreased ADAP–SLP-76 binding. Therefore, the data suggest that changes in redox balance control the association of SHP-2 with the Gads–SLP-76 complex and its ability to dephosphorylate substrate proteins. The interactions that lead SHP-2 to be recruited to SLP-76 are, as of yet, unclear. In SLP-76-deficient cells, co-immunoprecipitation of SHP-2 with Gads appeared unaffected, suggesting that SLP-76 itself or proteins recruited to Gads via SLP-76 (Vav1, Nck, Itk) did not recruit SHP-2 to the complex. A major SHP-2-binding protein is the adapter Gab2 (Yamasaki et al, 2001), which binds the SH3 domains of Grb2 and Gads (Yamasaki et al, 2003). In our hands, Gab2 was not detected in Grb2 immunoprecipitates (data not shown), while association with Gads was readily detected. Gab2 and SLP-76 were shown to compete for binding to the C-terminal SH3 domain of Gads (Yamasaki et al, 2003), while it is unclear if any proteins bind the N-terminal SH3 domain of Gads (Liu et al, 2001). Therefore, in our working model (Figure 7 Despite its proximity to many proteins in the Gads–SLP-76 complex, the effects of SHP-2 and ROS are selective. Phosphorylation or co-immunoprecipitation of proteins such as SLP-76 itself and PLCγ1 was not affected by expression of SHP-2(C/S) or by removing ROS with Prx II. Because Gads and PLCγ1 promote association of SLP-76 with LAT (Houtman et al, 2004), the data suggest that SHP-2 does not affect formation of the multi-adapter complex (LAT–Gads–SLP-76) but does selectively dephosphorylate proteins bound to that complex. The findings suggest that Vav1 and ADAP are direct substrates of SHP-2. Phosphorylation of total ADAP and total Vav1 was augmented by expression of SHP-2(C/S), and if only the pools of Vav1 or ADAP that were associated with Gads–SLP-76 were analyzed, this effect was magnified. These data support the notion of a localized and selective effect of SHP-2 on proteins in the Gads–SLP-76 complex upon TCR triggering. Our findings are further supported by a recent report that SHP-2 regulates Vav1 phosphorylation and Rho activation in rat aortic smooth muscle cells (Wakino et al, 2004). Y174 in Vav1 contributes to maintenance of a closed or inactive conformation for Vav1, and mutation of this residue leads to a constitutively active protein with transforming activity (Turner and Billadeau, 2002). Thus, SHP-2 localization to SLP-76 may control the activation of Vav1 bound to phosphorylated SLP-76, inhibiting subsequent activation of Rho family proteins, Rho, Rac1/2 or cdc42. It is not clear why Prx II expression did not further inhibit Vav1 phosphorylation. Vav1 has multiple phosphorylation sites whose phosphorylation may be affected by other redox-sensitive elements. In contrast to Vav1, tyrosine phosphorylation of ADAP promotes binding to the SH2 domain in SLP-76 (Peterson, 2003). There is still some controversy as to which tyrosine(s) mediates ADAP–SLP-76 association (Raab et al, 1999; Boerth et al, 2000). All the same, decreased SHP-2 activity, either through expression of SHP-2(C/S) or through ROS generation, promotes co-immunoprecipitation of ADAP with Gads–SLP-76. Conversely, augmenting SHP-2 activity through SHP-2 WT expression or quenching ROS with Prx II inhibited ADAP phosphorylation and co-precipitation with Gads–SLP-76. Thus, association of Vav1 with SLP-76 is SHP-2 independent, while ADAP–SLP-76 binding is sensitive to SHP-2 and changes in redox balance. ADAP appears to be required for TCR-induced clustering of LFA-1 and associated changes in adhesion of antigen-stimulated T cells (Peterson, 2003). Interaction of ADAP with SLP-76 may be required for TCR-induced LFA-1 clustering (Myung et al, 2001), although this remains to be demonstrated. ADAP may regulate T-cell adhesion through the adapter SKAP55 (Wang et al, 2003), or via Ena/VASP family members, which may affect integrin clustering through effects on cytoskeletal elements (Krause et al, 2000). Because association of ADAP with these proteins is independent of ADAP phosphorylation, redox regulation of ADAP–SLP-76 interactions may be a critical regulatory step in TCR-induced adhesion. Alternatively, Fyn association with ADAP is dependent upon ADAP phosphorylation (Peterson, 2003), so Fyn recruitment to a Gads–SLP-76 complex may also be altered by changes in redox balance. The biological role of SHP-2 in T cells has been difficult to ascertain because of the unavailability of SHP-2-deficient lymphocytes (Qu et al, 2001). Frearson and Alexander (1998) showed that expression of SHP-2(C/S) inhibited TCR-induced ERK activation, suggesting a positive role for SHP-2 in T cells. Conversely, a negative role for SHP-2 in activation of the PI3K pathway was also proposed in T cells (Yamasaki et al, 2001). The current data support a negative role for SHP-2 in regulating ‘inside-out' signals from TCR stimulation leading to LFA-1 clustering and adhesion. By extension, TCR-induced ROS generation serves to promote TCR signaling in this context. In conclusion, the current study has identified SHP-2 as a biological target of TCR-induced ROS. A recent report showing integrin-induced association of SHP-2 with the antioxidant enzyme catalase (Yano et al, 2004) suggests that redox regulation may be a common element in signaling pathways and that mechanisms to protect SHP-2 from oxidation have evolved. Furthermore, the data suggest that redox regulation of SHP-2 modulates TCR-induced LFA-1 clustering and adhesion. This implies that endogenous ROS or proinflammatory conditions may promote antigen-induced adhesion and arrest prior to extravasation and recruitment to the periphery. In the case of T cells, the effects may be via modulation of phosphorylation and/or association of key effector proteins within the protein complex formed through the adapters Gads–SLP-76. Thus, based upon the data, we hypothesize that localized production of ROS upon TCR triggering selectively shifts the balance between kinases and phosphatases to modulate T-cell function and immune responses. Materials and methods Antibodies and reagents Antibodies to Fyb/SLAP-130, c-Cbl, SHP-2, Grb2, ZAP-70, SHP-1, Vav1 and Shc were from Transduction Labs/BD-Biosciences (San Jose, CA). Antibodies to Vav1, Cbl, SHP-2, Grb2, Vav1 (pY174) and SHP-1 were from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to LAT, SLP 76, Gads, Vav1, Gab2, phosphotyrosine (4G10) and HRP-anti-sheep IgG were from Upstate Biotechnology Inc. (Lake Placid, NY). HA-tagged proteins were immunoprecipitated using the Profound HA-Tag IP/Co-IP Kit (Pierce, Rockford, IL). Anti-human ADAP was provided by Dr G Koretzky (University of Pennsylvania), and polyclonal anti-LAT sera was provided by Dr L Samelson (NICHD, NIH). The mixture of anti-PLCγ1 antibodies for immunoblot was from Dr SG Rhee (NHLBI, NIH) and anti-human LFA-1 (TS2/4) serum was provided by Dr L Zhang (University of Maryland School of Medicine). All other chemicals were obtained from Sigma (St Louis, MO) and all cell culture supplies were from Life Technologies (Carlsbad, CA). Plasmids Mammalian expression vectors for green fluorescent protein (GFP; EGFP-N1) and Prx II have been described previously (Devadas et al, 2002). Mammalian expression vectors for wild-type and catalytically inactive SHP-2 (SHP-2 C459S) have been described previously (Yu et al, 2003). The cDNA from these vectors was subcloned into pcDNA3.1/His and pCMV-HA vectors (Clontech, Palo Alto, CA) to make expression vectors for (His)6-tagged- and HA-tagged SHP-2 proteins, respectively. The mammalian expression vector for SHP-1(C/S) has been described previously (Yu et al, 2005). Cells The human T leukemic cell line, Jurkat (ATCC, Rockville, MD), was maintained in exponential growth phase in RPMI 1640 medium supplemented with 10% FBS, antibiotics and 50 μM 2-mercaptoethanol (complete medium). SLP-76-deficient Jurkat cells (J.14) were generously provided by Dr A Weiss (University of California, San Francisco). Mouse and human T blasts were prepared essentially as previously described (Jackson et al, 2004). PEO-iodoacetyl biotin labeling for detection of oxidized thiols Jurkat T cells or mouse T blasts were serum-starved and subsequently stimulated with anti-CD3 as described previously (Kwon et al, 2003; Jackson et al, 2004). Alternatively, cells were treated with graded concentrations of hydrogen peroxide for 5 min. Cells were lysed for 1 h at 25°C in an anaerobic chamber with 1 ml of O2-free lysis buffer (20 mM HEPES (pH 7.0), 1% Triton X-100, 10% glycerol, 2 mM EGTA, 10 mM β-glycerophosphate, 20 mM NaF, 10 μg/ml aprotinin and leupeptin, and 1 mM AEBSF) containing 0.4 mM PEO-iodoacetyl biotin (Pierce). Biotin incorporation into immunoprecipitated proteins was detected by Western blotting with HRP-conjugated streptavidin and ECL. ‘Positive' labeling of oxidized thiols was performed as described (Kwon et al, 2004). Briefly, T cells were lysed under anaerobic conditions and all free thiols were masked with 10 mM NEM and 10 mM iodoacetamide. Reversibly oxidized thiols were re-reduced with 4 mM DTT in the anaerobic chamber and then were labeled with 1 mM PEO-iodoacetyl biotin. Biotinylated proteins were precipitated with Neutravidin-agarose and the bound proteins were separated by SDS–PAGE. Cell adhesion assays Adhesion assays were performed essentially as described with minor modifications (Epler et al, 2000). LumiNunc Maxi-Sorp 96-well plates were coated with 1 μg/well fibronectin (from A Belkin, University of Maryland School of Medicine). Jurkat cells were transfected with 3 μg of β-galactosidase-coding plasmid and 15 μg of an empty vector, or expression plasmids for genes encoding SHP-2(C/S), SHP-2 WT or Prx II. Following incubation for 16 h, viable cells were precoated with anti-CD3 on ice as above. Cells (50 000 cells/well) were added to wells with anti-mouse IgG (2 μg/ml), incubated at 4°C for 1 h and then in a 37°C water bath for 30 min. Plates were washed gently and bound cells were assayed for β-galactosidase using the Gal-Screen System (Applied Biosystems, Bedford, MA). Fluorescence microscopy analysis Paraformaldehyde-fixed cells were incubated with anti-human LFA-1 (TS2/4) serum in PBS/0.2% BSA for 1 h on ice. After staining with Texas red-conjugated goat anti-mouse IgG1 (Southern Biotech, Birmingham), cells were plated on poly-L-lysine-coated slides and were visualized by fluorescent microscopy (Nikon Eclipse E400 microscope with a Photometrics CCD camera). Image capture was analyzed using Cool SNAP v.1.1. For each experiment, about 50 randomly selected GFP-positive cells were analyzed for LFA-1 staining pattern. Cells were divided into quadrants and were considered to have clustered LFA-1 if the staining pattern showed LFA-1 polarized to one of the quadrants of the cell. Immunoprecipitation and Western blotting Cells were lysed in ice-cold lysis buffer containing 1% Nonidet P-40 (v/v) in 20 mM HEPES (pH 7. 4) and 130 mM NaCl. The lysis buffer contained 10% glycerol, 1 mM Na4VO3, 2 mM EDTA, 10 mM β-glycerophosphate, 20 mM NaF, 10 μg/ml aprotinin and leupeptin, and 1 mM AEBSF. After centrifugation, the cell lysates were precleared with protein G-Sepharose 4B (Amersham) at 4°C and were immunoprecipitated with the indicated antibodies and protein G-Sepharose 4B. The beads were washed three times with lysis buffer. Cell lysates were subjected to immunoblot analysis essentially as described (Jackson et al, 2004). Densitometric analysis was performed using Personal Densitometer SI (Amersham Biosciences, Piscataway, NJ). Supplementary Figure 1 Click here to view.(221K, pdf) Supplementary Figure 2 Click here to view.(337K, pdf) Supplementary Figure 3 Click here to view.(258K, pdf) Supplementary Figure 4 Click here to view.(283K, pdf) Acknowledgments We thank Dr G Koretzky, Dr L Samelson, Dr SG Rhee and Dr A Weiss for generously providing reagents for this study. We also thank Dr D Leitenberg and Dr A Keegan for critical review of the manuscript. This work was supported by a Scientist Development Grant and a Grant-In-Aid to MSW from the American Heart Association. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Mol Cell. 2002 Feb; 9(2):387-99.
[Mol Cell. 2002]J Biol Chem. 2001 Jun 15; 276(24):21938-42.
[J Biol Chem. 2001]J Biol Chem. 1998 Jun 12; 273(24):15022-9.
[J Biol Chem. 1998]Sci STKE. 2000 Oct 10; 2000(53):pe1.
[Sci STKE. 2000]J Biol Chem. 2001 Jun 15; 276(24):21938-42.
[J Biol Chem. 2001]J Biol Chem. 2004 Sep 3; 279(36):37716-25.
[J Biol Chem. 2004]J Biol Chem. 1998 Jun 19; 273(25):15366-72.
[J Biol Chem. 1998]J Biol Chem. 2001 Sep 7; 276(36):33478-87.
[J Biol Chem. 2001]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]J Exp Med. 2002 Jan 7; 195(1):59-70.
[J Exp Med. 2002]Free Radic Biol Med. 2003 Aug 15; 35(4):406-17.
[Free Radic Biol Med. 2003]Proc Natl Acad Sci U S A. 1992 Nov 1; 89(21):10306-10.
[Proc Natl Acad Sci U S A. 1992]Nat Immunol. 2003 Feb; 4(2):110-6.
[Nat Immunol. 2003]Immunol Rev. 2003 Feb; 191():139-47.
[Immunol Rev. 2003]Sci STKE. 2000 Dec 19; 2000(63):re1.
[Sci STKE. 2000]Oncogene. 2001 Oct 1; 20(44):6284-90.
[Oncogene. 2001]Immunity. 2001 Dec; 15(6):1011-26.
[Immunity. 2001]Free Radic Biol Med. 2003 Aug 15; 35(4):406-17.
[Free Radic Biol Med. 2003]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]J Exp Med. 1998 May 4; 187(9):1417-26.
[J Exp Med. 1998]Anal Biochem. 2000 Aug 1; 283(2):214-21.
[Anal Biochem. 2000]Free Radic Biol Med. 2003 Aug 15; 35(4):406-17.
[Free Radic Biol Med. 2003]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]Trends Biochem Sci. 2003 Jun; 28(6):284-93.
[Trends Biochem Sci. 2003]J Biol Chem. 1994 Feb 25; 269(8):5602-11.
[J Biol Chem. 1994]Proc Natl Acad Sci U S A. 2004 Nov 23; 101(47):16419-24.
[Proc Natl Acad Sci U S A. 2004]J Exp Med. 2002 Jan 7; 195(1):59-70.
[J Exp Med. 2002]Curr Opin Cell Biol. 1997 Apr; 9(2):193-204.
[Curr Opin Cell Biol. 1997]J Exp Med. 1998 May 4; 187(9):1417-26.
[J Exp Med. 1998]Circ Res. 2004 Sep 3; 95(5):e45-55.
[Circ Res. 2004]J Biol Chem. 2001 Nov 30; 276(48):45175-83.
[J Biol Chem. 2001]Nat Rev Immunol. 2002 Jul; 2(7):476-86.
[Nat Rev Immunol. 2002]Trends Biochem Sci. 2003 Jun; 28(6):284-93.
[Trends Biochem Sci. 2003]Free Radic Biol Med. 2003 Aug 15; 35(4):406-17.
[Free Radic Biol Med. 2003]Science. 2001 Sep 21; 293(5538):2260-3.
[Science. 2001]Science. 2001 Sep 21; 293(5538):2263-5.
[Science. 2001]Immunol Rev. 2003 Apr; 192():113-21.
[Immunol Rev. 2003]Curr Opin Cell Biol. 2003 Apr; 15(2):247-54.
[Curr Opin Cell Biol. 2003]Curr Opin Cell Biol. 2005 Apr; 17(2):183-9.
[Curr Opin Cell Biol. 2005]Biochemistry. 1999 Nov 23; 38(47):15407-16.
[Biochemistry. 1999]J Biol Chem. 1998 Jun 19; 273(25):15366-72.
[J Biol Chem. 1998]J Biol Chem. 1999 Dec 3; 274(49):34543-6.
[J Biol Chem. 1999]Nature. 2003 Jun 12; 423(6941):769-73.
[Nature. 2003]Trends Biochem Sci. 2003 Jun; 28(6):284-93.
[Trends Biochem Sci. 2003]Mol Cell. 2002 Feb; 9(2):387-99.
[Mol Cell. 2002]J Biol Chem. 2005 Mar 18; 280(11):10298-304.
[J Biol Chem. 2005]J Exp Med. 1998 May 4; 187(9):1417-26.
[J Exp Med. 1998]Mol Cell. 2002 Feb; 9(2):387-99.
[Mol Cell. 2002]J Biol Chem. 2001 Nov 30; 276(48):45175-83.
[J Biol Chem. 2001]Mol Cell Biol. 2003 Apr; 23(7):2515-29.
[Mol Cell Biol. 2003]Oncogene. 2001 Oct 1; 20(44):6284-90.
[Oncogene. 2001]Biochemistry. 2004 Apr 13; 43(14):4170-8.
[Biochemistry. 2004]Circ Res. 2004 Sep 3; 95(5):e45-55.
[Circ Res. 2004]Nat Rev Immunol. 2002 Jul; 2(7):476-86.
[Nat Rev Immunol. 2002]Immunol Rev. 2003 Apr; 192():113-21.
[Immunol Rev. 2003]J Biol Chem. 1999 Jul 23; 274(30):21170-9.
[J Biol Chem. 1999]J Biol Chem. 2000 Feb 18; 275(7):5143-52.
[J Biol Chem. 2000]Immunol Rev. 2003 Apr; 192():113-21.
[Immunol Rev. 2003]Immunity. 2001 Dec; 15(6):1011-26.
[Immunity. 2001]Nat Immunol. 2003 Apr; 4(4):366-74.
[Nat Immunol. 2003]J Cell Biol. 2000 Apr 3; 149(1):181-94.
[J Cell Biol. 2000]Blood. 2001 Feb 15; 97(4):911-4.
[Blood. 2001]J Exp Med. 1998 May 4; 187(9):1417-26.
[J Exp Med. 1998]J Biol Chem. 2001 Nov 30; 276(48):45175-83.
[J Biol Chem. 2001]FEBS Lett. 2004 Nov 19; 577(3):327-32.
[FEBS Lett. 2004]J Exp Med. 2002 Jan 7; 195(1):59-70.
[J Exp Med. 2002]Oncogene. 2003 Sep 4; 22(38):5995-6004.
[Oncogene. 2003]J Immunol. 2005 Jan 15; 174(2):1013-9.
[J Immunol. 2005]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]Free Radic Biol Med. 2003 Aug 15; 35(4):406-17.
[Free Radic Biol Med. 2003]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]Proc Natl Acad Sci U S A. 2004 Nov 23; 101(47):16419-24.
[Proc Natl Acad Sci U S A. 2004]J Immunol. 2000 Nov 1; 165(9):4941-9.
[J Immunol. 2000]Nat Immunol. 2004 Aug; 5(8):818-27.
[Nat Immunol. 2004]